Colloidal Silver: A Proven Defender Against Pathogens
Colloidal silver has been shown to effectively eliminate COVID-19 and the vast majority of harmful viruses and bacteria—often in as little as five minutes. Scientific research, including studies published by reputable organizations such as the National Center for Biotechnology Information (NCBI), supports its powerful antimicrobial properties. The NCBI, part of the U.S. National Library of Medicine and the National Institutes of Health, has published findings highlighting the effectiveness of silver nanoparticles in combating COVID-19. You can read the full study here.
The Debate Around Colloidal Silver
Like many natural remedies, colloidal silver has its share of supporters and detractors. The arguments against it often come from entities with financial interests in pharmaceutical alternatives, where the profit margins dwarf those of colloidal silver. While debates can make it hard to discern the truth, we encourage informed decisions based on credible evidence and personal experience.
Why We Recommend Making Your Own
We use colloidal silver, we make it, and we sell it—but we believe the best way to ensure quality and purity is to make your own. By producing it yourself, you gain full control over the process and peace of mind about what you’re using. Whether you choose to buy it or make it, we recommend trying colloidal silver for yourself to see its potential benefits firsthand.
Discover the Potential
With its broad-spectrum antimicrobial action and scientific backing, colloidal silver is a versatile supplement worth exploring. Start your journey toward better health by learning more and experiencing it for yourself.
Brigham Young University Microbiology Department Report
Brigham Young University (BYU), a globally recognized leader in academic research, conducted a study through its Microbiology Department in 1999 to evaluate the effectiveness of a colloidal silver solution. The findings, published after rigorous testing, provide compelling evidence of colloidal silver’s broad-spectrum antimicrobial properties.
The results are clear and powerful: colloidal silver demonstrated significant effectiveness in neutralizing harmful microorganisms. These findings further substantiate the growing body of research supporting colloidal silver as a potent, natural solution for combating infections.
BYU’s reputation as a world-class institution lends credibility to these results, making them an essential consideration for anyone exploring natural health alternatives. The evidence speaks for itself.
BACTERIA TESTING
Microbiology Department
Brigham Young University
775 WIDB
P.O. Box 25253
Provo, Utah 84602-5253
May 13, 1999
…Silver Supplement has been tested against the following organisms.
Staphylococcus aureus (Pneumonia, eye infections, skin infections (boils, impetigo, cellulitis, and post-operative wound infections), toxic shock syndrome, meningitis, food poisoning, osteomyelitis, and many others) inhibited @ 2.5 ppm and killed @ 5 ppm. 1/22/99 BYU Report.
Shigella boydii (Bacillary dysentery–characterized by severe cramping abdominal pain and bloody diarrhea) inhibited @ 1.25 ppm and killed @ 2.5 ppm. 1/22/99 BYU Report.
Salmonella arizona (Food poisoning, etc.) inhibited @ 2.5 ppm and killed @ 5 ppm. 1/28/99 BYU Report.
Salmonella typhimurium (Food poisoning and enteric fever) inhibited and killed at a concentration of 2.5 ppm. 6/7/99 BYU Report.
E. coli (Food poisoning, urinary tract infections, traveler’s diarrhea, diarrhea in infants, respiratory tract infections, and wound infections) inhibited and killed @ 2.5 ppm. 1/22/99 BYU Report.
Haemophilus influenzae (Otitis media (ear infection), pneumonia, meningitis, throat and sinus infections (including epiglottitis in children and sinusitis), and suppurative arthritis in children) inhibited and killed @ 1.25 ppm. 1/22/99 BYU Report.
Enterobacter aerogenes ( wound infections, urinary tract infections, bacteremia, and meningitis) inhibited and killed at a concentration of 2.5 ppm. 6/7/99 BYU Report.
Enterobacter cloacae ( causes ilnesses similar to the E. aerogenes) inhibited and killed at a concentration of 5 ppm. 6/7/99 BYU Report.
Klebsiella pneumoniae (lower respiratory tract infections, nosocomial infections (infections spread in hospitals), urinary tract and wound infections, and bacteremia) inhibited and killed @ 2.5 ppm. 1/28/99 BYU Report.
Klebsiella oxytoca (Similar to those infections caused by K. pneumoniae) inhibited and killed at a concentration of 2.5 ppm. 6/7/99BYU Report.
Pseudomonas aeruginosa (severe burn and wound infections, keratitis, pneumonia, meningitis, nosocomial infections, urinary tract infections, etc.) inhibited @ 2.5 ppm and killed @ 5 ppm. 1/22/99 BYU Report.
Streptococcus pneumoniae (pneumonia, meningitis, sinusitis, otitis media (ear infection) inhibited @ 2.5 ppm and killed @ 5 ppm. 4/21/99 BYU Report.
Streptococcus pyogenes (skin infections, upper respiratory infections (i.e. strep throat) impetigo, hospital-acquired infections, scarlet fever, etc.) inhibited and killed @ 1.25 ppm. 1/22/99 BYU Report.
Streptococcus faecalis (Urinary tract infections, endocarditis, wound infections, etc.) inhibited @ 2.5 ppm and killed @ 5 ppm. 1/22/99 BYU Report.\
Streptococcus mutans (A major cause dental plaque and tooth decay etc.) inhibited and killed @ 5 ppm. 2/3/99 BYU Report.
Streptococcus gordonii (Tooth decay, also implicated in infective endocarditis-an infection of the heart valves) inhibited and killed @ 5 ppm. BYU Report 2/12/99.\
David A. Revelli
Microbiologist
Brigham Young University
Dr. Ron W. Leavitt, Ph.D.
Professor of Microbiology/Molecular Biology